Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$89.78

1.68 (1.91%)

18:07
04/12/19
04/12
18:07
04/12/19
18:07

Alnylam's Givosiran study met primary efficacy endpoint in AHP treatment

Alnylam announced "positive complete results" from the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 in development for the treatment of acute hepatic porphyria, or AHP. The full ENVISION results demonstrated a 74% mean and 90% median reduction in the primary endpoint measure of annualized rate of composite attacks in patients on givosiran relative to placebo during the six-month double-blind period. In addition, givosiran achieved statistically significant positive results for five of nine secondary endpoints, with an overall safety and tolerability profile that the company believes is encouraging, especially in this high unmet need disease. Adverse events were reported in 89.6% of givosiran patients and 80.4% of placebo patients; serious adverse events were reported in 20.8% of givosiran patients and 8.7% of placebo patients. Ninety-three of 94% , or 99%, enrolled in the open-label extension period of the study. Based on the ENVISION results, the company plans to complete its rolling submission of a New Drug Application and file a Marketing Authorisation Application in mid-2019.

  • 13

    Apr

  • 25

    Apr

ALNY Alnylam
$89.78

1.68 (1.91%)

04/08/19
PIPR
04/08/19
NO CHANGE
Target $142
PIPR
Overweight
Alnylam alliance with Regeneron a 'clear positive,' says Piper Jaffray
Alnylam Pharmaceuticals (ALNY) today concluded its 2014 RNAi discovery collaboration with Sanofi (SNY) and announced a new five-year RNAi drug discovery alliance with Regeneron Pharmaceuticals (REGN), Piper Jaffray analyst Edward Tenthoff tells investors in a research note. Alnylam will receive $400M in cash and Regeneron will make a $400M equity investment at $90 per Alnylam share, bringing its estimated pro forma cash to $2.3B, adds the analyst. He believes the alliance is a "clear positive for Alnylam "dramatically expanding" its RNAi drug discovery capabilities and strengthening its balance sheet to advance its own orphan disease programs. Tenthoff reiterates an Overweight rating on Alnylam with a $142 price target. The stock in early trading is down 3%, or $2.95, to $89.94.
04/09/19
BMOC
04/09/19
NO CHANGE
Target $119
BMOC
Outperform
Alnylam price target raised to $119 from $106 at BMO Capital
BMO Capital analyst Do Kim raised his price target on Alnylam (ALNY) to $119 and kept his Outperform rating after its announced Regeneron (REGN) partnership on ocular / CNS diseases and liver-related diseases. The analyst expects the collaboration to result in favorable economics that also gives Alnylam an opportunity to co-promote its CNS program, but warns that some pressure on the stock is possible since the equity investment component by Regeneron at $90 per share was $3 below Friday's close.
04/09/19
LEER
04/09/19
NO CHANGE
Target $70
LEER
Market Perform
Alnylam price target raised to $70 from $65 at SVB Leerink
SVB Leerink analyst Mani Foroohar raised his price target for Alnylam (ALNY) to $70 from $65 after the company announced a collaboration with Regeneron (REGN) to develop and commercialize RNAi therapeutics with a focus on CNS and ocular indications, along with liver-directed NASH therapies and cemdisiran in combination with pozelimab. The analyst believes the terms of the deal, which includes a $400M upfront payment and a $400M equity investment in Alnylam at $90/share, are favorable for Alnylam. Foroohar reiterates a Market Perform rating on Alnylam's shares.
04/11/19
EVER
04/11/19
INITIATION
Target $120
EVER
Outperform
Alnylam initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Alnylam with an Outperform rating and a price targets of $120, citing the "strength of its Onpattro franchise and high modality modularity." The analyst contends that the company's modular platform enables its "sustainable growth opportunities", points to its Lumasiran Phase 3 results being a "resounding win", and also notes that all of the company's pipeline segments are advancing.

TODAY'S FREE FLY STORIES

CTRC

Centric Brands

$3.84

-0.04 (-1.03%)

16:16
04/22/19
04/22
16:16
04/22/19
16:16
Hot Stocks
Centric Brands receives notification of deficiency from Nasdaq »

Centric Brands Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTD

Trade Desk

$211.14

12.38 (6.23%)

16:16
04/22/19
04/22
16:16
04/22/19
16:16
Initiation
Trade Desk initiated  »

Trade Desk initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 09

    May

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
04/22/19
04/22
16:16
04/22/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZION

Zions Bancorp

$46.68

-0.63 (-1.33%)

16:15
04/22/19
04/22
16:15
04/22/19
16:15
Earnings
Zions Bancorp reports Q1 EPS $1.04, consensus $1.05 »

Reports Q1 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

WHR

Whirlpool

$139.39

0.35 (0.25%)

16:15
04/22/19
04/22
16:15
04/22/19
16:15
Hot Stocks
Breaking Hot Stocks news story on Whirlpool »

Whirlpool sees FY19 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

SIMO

Silicon Motion

16:14
04/22/19
04/22
16:14
04/22/19
16:14
Downgrade
Silicon Motion rating change  »

Silicon Motion downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 28

    May

CDNS

Cadence Design

$64.23

0.865 (1.37%)

16:14
04/22/19
04/22
16:14
04/22/19
16:14
Hot Stocks
Cadence Design reports Q1 operating margin 32% vs 28% last year »

Cadence Design CFO John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 02

    May

RCKT

Rocket Pharmaceuticals

$17.80

0.93 (5.51%)

16:14
04/22/19
04/22
16:14
04/22/19
16:14
Initiation
Rocket Pharmaceuticals initiated  »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHR

Whirlpool

$139.31

0.27 (0.19%)

16:14
04/22/19
04/22
16:14
04/22/19
16:14
Hot Stocks
Whirlpool CFO says 'on track' to meet FY earnings, cash flow guidance »

"In addition to our…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

EGP

EastGroup Properties

$109.43

-1.28 (-1.16%)

16:13
04/22/19
04/22
16:13
04/22/19
16:13
Earnings
EastGroup Properties raises FY19 FFO view to $4.84-$4.94, consensus $4.85 »

Raises the mid-point of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 06

    May

  • 07

    May

  • 04

    Jun

HARP

Harpoon Therapeutics

$11.63

-1.405 (-10.78%)

16:13
04/22/19
04/22
16:13
04/22/19
16:13
Initiation
Harpoon Therapeutics initiated  »

Harpoon Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHR

Whirlpool

$139.34

0.3 (0.22%)

16:12
04/22/19
04/22
16:12
04/22/19
16:12
Hot Stocks
Whirlpool backs FY19 free cash flow view approximately $800M-$900M »

The company reaffirms its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

EGP

EastGroup Properties

$109.51

-1.2 (-1.08%)

16:12
04/22/19
04/22
16:12
04/22/19
16:12
Earnings
EastGroup Properties reports Q1 FFO $1.20, consensus $1.18 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 06

    May

  • 07

    May

  • 04

    Jun

CDNS

Cadence Design

$64.24

0.88 (1.39%)

16:11
04/22/19
04/22
16:11
04/22/19
16:11
Earnings
Cadence Design raises FY19 EPS to $2.04-$2.12 from $1.97-$2.07, consensus $2.03 »

Raises 2019 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 02

    May

WHR

Whirlpool

$139.44

0.4 (0.29%)

16:11
04/22/19
04/22
16:11
04/22/19
16:11
Earnings
Breaking Earnings news story on Whirlpool »

Whirlpool backs FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

WHR

Whirlpool

$139.42

0.38 (0.27%)

16:10
04/22/19
04/22
16:10
04/22/19
16:10
Earnings
Whirlpool reports Q1 adjusted EPS $3.11, consensus $2.87 »

Reports Q1 revenue $4.8B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

MINI

Mobile Mini

$34.65

0.67 (1.97%)

16:09
04/22/19
04/22
16:09
04/22/19
16:09
Earnings
Mobile Mini reports Q1 adjusted EPS 41c, consensus 38c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

  • 07

    May

KIDS

OrthoPediatrics

$36.94

0.51 (1.40%)

16:09
04/22/19
04/22
16:09
04/22/19
16:09
Hot Stocks
OrthoPediatrics announces licensing partnership with CoorsTek Medical »

OrthoPediatrics Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

CDNS

Cadence Design

$64.20

0.84 (1.33%)

16:09
04/22/19
04/22
16:09
04/22/19
16:09
Earnings
Cadence Design sees Q2 EPS 52c-54c, consensus 50c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 02

    May

ADC

Agree Realty

$64.54

-0.77 (-1.18%)

16:08
04/22/19
04/22
16:08
04/22/19
16:08
Hot Stocks
Agree Realty raises FY19 acquisition guidance view to $450M-$500M »

The company sated,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 25

    Apr

  • 04

    Jun

ZSAN

Zosano Pharma

$3.65

0.24 (7.04%)

16:08
04/22/19
04/22
16:08
04/22/19
16:08
Initiation
Zosano Pharma initiated  »

Zosano Pharma initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMBS

Rambus

$11.84

-0.06 (-0.50%)

16:08
04/22/19
04/22
16:08
04/22/19
16:08
Hot Stocks
Breaking Hot Stocks news story on Rambus »

Rambus sees Q2 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 25

    Apr

  • 15

    May

  • 16

    May

CDNS

Cadence Design

$64.20

0.84 (1.33%)

16:08
04/22/19
04/22
16:08
04/22/19
16:08
Earnings
Cadence Design reports Q1 adjusted EPS 54c, consensus 49c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 02

    May

RMBS

Rambus

$11.84

-0.065 (-0.55%)

16:07
04/22/19
04/22
16:07
04/22/19
16:07
Earnings
Rambus reports Q1 adjusted EPS (8c), may not compare to consensus 23c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 25

    Apr

  • 15

    May

  • 16

    May

ADC

Agree Realty

$64.35

-0.96 (-1.47%)

16:07
04/22/19
04/22
16:07
04/22/19
16:07
Earnings
Agree Realty reports Q1 Core FFO 74c, consensus 74c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 25

    Apr

  • 04

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.